ALRN - エイルロン・セラピュ―ティクス （Aileron Therapeutics Inc.） エイルロン・セラピュ―ティクスALRNのチャート
ALRNの企業情報
| symbol | ALRN |
|---|---|
| 会社名 | Aileron Therapeutics Inc （エイルロン・セラピュ―ティクス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 エルロン・セラピューティクス(Aileron Therapeutics Inc.)は米国を拠点とする臨床段階のバイオ医薬品会社である。同社はステープルペプチドと呼ばれる治療薬を開発し、商品化する。同社はまた、癌、内分泌および代謝性疾患および炎症を含む治療領域にわたってステープルペプチド薬物パイプラインを開発する。同社は固型と血液悪性腫瘍のスペクトルにおいて有効性・安全性を提供するリード・オンコロジー・プログラムを提供する。同社のリード製品候補ALRN-6924は癌の治療用腫瘍抑制タンパク質p53を標的とする。同社は標準的療法に非突然変異型・野生型p53を発現する固形腫瘍・リンパ腫を有する成人患者において、ALRN-6924の第I相臨床試験を実施する。ALRN-6924は天然p53サプレッサータンパク質のマウス（MDM2）およびMDMXを標的とすることによって、p53媒介細胞死を再活性化できる。 エイルロン・セラピュ―ティクスはアメリカのバイオ医薬品企業。臨床段階で、治療用ペプチド薬品の開発・商品化に従事する。がん、内分泌および代謝性疾患、炎症などの治療用ペプチドを開発し、同社パイプライン「ALRN-6924」は多種多様ながんの治療向けに腫瘍抑制因子p53をタ―ゲットとする。本社はマサチュ―セッツ州ケンブリッジ。 |
| 本社所在地 | 281 Albany Street Cambridge MA 02139 USA |
| 代表者氏名 | Jeffrey A. Bailey ジェフリー・A・ベイリー |
| 代表者役職名 | Chairman of the Board 取締役会会長 |
| 電話番号 | +1 617-995-0900 |
| 設立年月日 | 37104 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2017年 |
| 従業員数 | － |
| url | www.aileronrx.com |
| nasdaq_url | https://www.nasdaq.com/symbol/alrn |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -30.72300 |
| 終値（lastsale） | 2.68 |
| 時価総額（marketcap） | 39496237.36 |
| 時価総額 | 時価総額（百万ドル） 38.31725 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 5.87125 |
| 当期純利益 | 当期純利益（百万ドル） -30.20300 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Aileron Therapeutics Inc revenues was not reported. Net loss applicable to common stockholders increased 79% to $17.1M. Higher net loss reflects Research and development increase of 64% to $9.7M (expense) General and administrative increase of 79% to $5.7M (expense) Stock-based Compensation in SGA increase from $264K to $1.6M (expense). |
ALRNのテクニカル分析
ALRNのニュース
Investing in Aileron Therapeutics Inc. (ALRN) might be an excellent idea, but the stock is currently overvalued/undervalued 2023/01/02 14:08:00 US Post News
In Friday’s session, Aileron Therapeutics Inc. (NASDAQ:ALRN) marked $2.37 per share, up from $1.87 in the previous session. While Aileron Therapeutics Inc. has overperformed by 26.56%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ALRN fell by -77.88%, with highs and lows ranging from $15.00 to […]
Aileron Therapeutics Regains Compliance with Nasdaq Listing Requirements 2022/11/30 12:00:00 GlobeNewswire
BOSTON, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives, today announced that it received written notice on November 28, 2022 from The Nasdaq Stock Market noting that Aileron has regained compliance with the minimum bid price requirement under Listing Rule 5550(a)(2), which requires the company to maintain a minimum closing bid price of $1.00 per share, and the matter is now closed. Nasdaq staff made this determination after Aileron’s closing bid price was above $1.00 per share for 10 consecutive business days from November 11, 2022 to November 25, 2022.
Aileron Therapeutics, Inc.: Aileron Therapeutics Announces a 1-for-20 Reverse Stock Split 2022/11/10 13:10:00 Finanz Nachrichten
BOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more pa…
Aileron Therapeutics GAAP EPS of -$0.07 beats by $0.01 2022/11/01 12:41:09 Seeking Alpha
Aileron Therapeutics press release (ALRN): Q3 GAAP EPS of -$0.07 beats by $0.01.Cash, cash equivalents, and investments on September 30, 2022, were $25.5 million, compared to…
Aileron Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights 2022/11/01 12:15:00 GlobeNewswire
BOSTON, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives today, reported financial results and business highlights for the third quarter ended September 30, 2022.
Investing in Aileron Therapeutics Inc. (ALRN) might be an excellent idea, but the stock is currently overvalued/undervalued 2023/01/02 14:08:00 US Post News
In Friday’s session, Aileron Therapeutics Inc. (NASDAQ:ALRN) marked $2.37 per share, up from $1.87 in the previous session. While Aileron Therapeutics Inc. has overperformed by 26.56%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ALRN fell by -77.88%, with highs and lows ranging from $15.00 to […]
Aileron Therapeutics Regains Compliance with Nasdaq Listing Requirements 2022/11/30 12:00:00 GlobeNewswire
BOSTON, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives, today announced that it received written notice on November 28, 2022 from The Nasdaq Stock Market noting that Aileron has regained compliance with the minimum bid price requirement under Listing Rule 5550(a)(2), which requires the company to maintain a minimum closing bid price of $1.00 per share, and the matter is now closed. Nasdaq staff made this determination after Aileron’s closing bid price was above $1.00 per share for 10 consecutive business days from November 11, 2022 to November 25, 2022.
Aileron Therapeutics, Inc.: Aileron Therapeutics Announces a 1-for-20 Reverse Stock Split 2022/11/10 13:10:00 Finanz Nachrichten
BOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more pa…
Aileron Therapeutics GAAP EPS of -$0.07 beats by $0.01 2022/11/01 12:41:09 Seeking Alpha
Aileron Therapeutics press release (ALRN): Q3 GAAP EPS of -$0.07 beats by $0.01.Cash, cash equivalents, and investments on September 30, 2022, were $25.5 million, compared to…
Aileron Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights 2022/11/01 12:15:00 GlobeNewswire
BOSTON, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives today, reported financial results and business highlights for the third quarter ended September 30, 2022.
Aileron Therapeutics Regains Compliance with Nasdaq Listing Requirements 2022/11/30 12:00:00 GlobeNewswire
BOSTON, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives, today announced that it received written notice on November 28, 2022 from The Nasdaq Stock Market noting that Aileron has regained compliance with the minimum bid price requirement under Listing Rule 5550(a)(2), which requires the company to maintain a minimum closing bid price of $1.00 per share, and the matter is now closed. Nasdaq staff made this determination after Aileron’s closing bid price was above $1.00 per share for 10 consecutive business days from November 11, 2022 to November 25, 2022.
Aileron Therapeutics, Inc.: Aileron Therapeutics Announces a 1-for-20 Reverse Stock Split 2022/11/10 13:10:00 Finanz Nachrichten
BOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more pa…
Aileron Therapeutics GAAP EPS of -$0.07 beats by $0.01 2022/11/01 12:41:09 Seeking Alpha
Aileron Therapeutics press release (ALRN): Q3 GAAP EPS of -$0.07 beats by $0.01.Cash, cash equivalents, and investments on September 30, 2022, were $25.5 million, compared to…
Aileron Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights 2022/11/01 12:15:00 GlobeNewswire
BOSTON, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives today, reported financial results and business highlights for the third quarter ended September 30, 2022.
Aileron Therapeutics to Present and Participate in a Fireside Chat at the Ladenburg Thalmann 2022 Healthcare Conference 2022/09/22 12:00:00 GlobeNewswire
BOSTON, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives, today announced that Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer, will give a corporate presentation and participate in a fireside chat at the Ladenburg Thalmann 2022 Healthcare Conference on Thursday, September 29, 2022, at 3:30 p.m. ET in New York, New York.